Miragen Therapeutics Stock Price, News & Analysis (NASDAQ:MGEN)

$5.57 +0.09 (+1.64 %)
(As of 02/25/2018 03:07 AM ET)
Previous Close$5.57
Today's Range$5.36 - $5.60
52-Week Range$5.01 - $18.00
Volume102,005 shs
Average Volume306,962 shs
Market Capitalization$158.30 million
P/E Ratio37.13
Dividend YieldN/A
Beta1.43

About Miragen Therapeutics (NASDAQ:MGEN)

Miragen Therapeutics logoSignal Genetics, Inc. is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company's diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test. The MyPRS test is a microarray-based gene expression profile (GEP), assay that measures the expression level of specific genes and groups of genes that are designed to predict an individual's long-term clinical outcome/prognosis, giving a basis for personalized treatment options. The Company's MyPRS test provides a whole-genomic expression profile of a patient's multiple myeloma (MM). The Company offers MyPRS test in its laboratory located in Little Rock, Arkansas. The Company is licensed to sell its test in all 50 states.

Receive MGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for MGEN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Laboratories & Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MGEN
CUSIPN/A
Phone720-643-5200

Debt

Debt-to-Equity Ratio0.04%
Current Ratio7.11%
Quick Ratio7.11%

Price-To-Earnings

Trailing P/E Ratio37.1333333333333
Forward P/E Ratio-4.13
P/E GrowthN/A

Sales & Book Value

Annual Sales$3.34 million
Price / Sales48.18
Cash FlowN/A
Price / CashN/A
Book Value($0.43) per share
Price / Book-12.95

Profitability

Trailing EPS$0.15
Net Income$-12,670,000.00
Net Margins-720.38%
Return on Equity-80.31%
Return on Assets-64.59%

Miscellaneous

Employees45
Outstanding Shares28,890,000

Miragen Therapeutics (NASDAQ:MGEN) Frequently Asked Questions

What is Miragen Therapeutics' stock symbol?

Miragen Therapeutics trades on the NASDAQ under the ticker symbol "MGEN."

How were Miragen Therapeutics' earnings last quarter?

Miragen Therapeutics, Inc. (NASDAQ:MGEN) released its earnings results on Wednesday, November, 8th. The medical research company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.39) by $0.12. The medical research company had revenue of $1.63 million for the quarter, compared to the consensus estimate of $0.72 million. Miragen Therapeutics had a negative return on equity of 80.31% and a negative net margin of 720.38%. View Miragen Therapeutics' Earnings History.

Where is Miragen Therapeutics' stock going? Where will Miragen Therapeutics' stock price be in 2018?

6 brokerages have issued twelve-month target prices for Miragen Therapeutics' shares. Their predictions range from $13.00 to $29.00. On average, they anticipate Miragen Therapeutics' stock price to reach $17.90 in the next twelve months. View Analyst Ratings for Miragen Therapeutics.

What are Wall Street analysts saying about Miragen Therapeutics stock?

Here are some recent quotes from research analysts about Miragen Therapeutics stock:

  • 1. Cann analysts commented, "MiRagen Therapeutics announced today positive new interim data from its phase I clinical trial of MRG-106 in patients with the mycosis fungoides (MF) form of cutaneous T-cell lymphoma (CTCL) will be presented on February 2, 2018, at the 10th Annual T-cell Lymphoma Forum in La Jolla, California. These positive results support MiRagen’s plans to initiate a phase II study of MRG-106 in CTCL in the second half of 2018. The data released today, along with the planned phase II trial design support our expectation that MRG-106 will be able to proceed to a registration phase II study, avoiding phase III trials." (2/2/2018)
  • 2. According to Zacks Investment Research, "Miragen Therapeutics, Inc. is a biopharmaceutical company. It develops microRNA biology, oligonucleotide chemistry, drugs and therapies for cancer, pathologic fibrosis, neuro-inflammatory and cardiovascular diseases. Miragen Therapeutics, Inc., formerly known as Signal Genetics, is headquartered in Boulder, Colorado. " (1/25/2018)
  • 3. Chardan Capital analysts commented, "We see 6 positives in the MRG-106 oral presentation at EORTC The MRG-106 oral presentation at EORTC shows promising signals on the mycosis fungoides form of CTCL. On Saturday, October 13th, at the European Organisation for Research and Treatment of Cancer (EORTC) Global Task Force meeting, miRagen Therapeutics presented new interim phase I data of microRNA-155 inhibitor, MRG-106, in the mycosis fungoides (MF) form of cutaneous t-cell lymphoma (CTCL). The results showed 22/23 (96%) of MRG-106-treated patients had improvements in skin disease, when treated with either subcutaneous (subQ) or intravenous MRG-106, as measured by the maximal change in the modified Severity Weighted Assessment Tool (mSWAT) score, which measures the severity of skin disease over a patient’s body." (10/16/2017)

Who are some of Miragen Therapeutics' key competitors?

Who owns Miragen Therapeutics stock?

Miragen Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (2.58%), Renaissance Technologies LLC (0.37%), Deutsche Bank AG (0.27%), Virtu Financial LLC (0.23%), Bank of New York Mellon Corp (0.21%) and Aveo Capital Partners LLC (0.12%). Company insiders that own Miragen Therapeutics stock include Adam Scott Levy, Bruce Booth, Kyle Lefkoff and Thomas E Hughes. View Institutional Ownership Trends for Miragen Therapeutics.

Who bought Miragen Therapeutics stock? Who is buying Miragen Therapeutics stock?

Miragen Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Deutsche Bank AG, Virtu Financial LLC, Aveo Capital Partners LLC, BlackRock Inc., Bank of New York Mellon Corp and Wells Fargo & Company MN. Company insiders that have bought Miragen Therapeutics stock in the last two years include Adam Scott Levy and Bruce Booth. View Insider Buying and Selling for Miragen Therapeutics.

How do I buy Miragen Therapeutics stock?

Shares of Miragen Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Miragen Therapeutics' stock price today?

One share of Miragen Therapeutics stock can currently be purchased for approximately $5.57.

How big of a company is Miragen Therapeutics?

Miragen Therapeutics has a market capitalization of $158.30 million and generates $3.34 million in revenue each year. The medical research company earns $-12,670,000.00 in net income (profit) each year or $0.15 on an earnings per share basis. Miragen Therapeutics employs 45 workers across the globe.

How can I contact Miragen Therapeutics?

Miragen Therapeutics' mailing address is 6200 LOOKOUT ROAD, BOULDER CO, 80301. The medical research company can be reached via phone at 720-643-5200 or via email at [email protected]


MarketBeat Community Rating for Miragen Therapeutics (MGEN)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  114 (Vote Outperform)
Underperform Votes:  80 (Vote Underperform)
Total Votes:  194
MarketBeat's community ratings are surveys of what our community members think about Miragen Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Miragen Therapeutics (NASDAQ:MGEN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $17.90$17.90$23.00$23.00
Price Target Upside: 102.26% upside122.64% upside144.16% upside143.39% upside

Miragen Therapeutics (NASDAQ:MGEN) Consensus Price Target History

Price Target History for Miragen Therapeutics (NASDAQ:MGEN)

Miragen Therapeutics (NASDAQ:MGEN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/2/2018CannReiterated RatingBuy$13.00LowView Rating Details
1/16/2018Chardan CapitalReiterated RatingBuyLowView Rating Details
1/12/2018OppenheimerInitiated CoverageOutperform$13.00HighView Rating Details
1/5/2018B. RileyInitiated CoverageBuy -> Buy$15.50HighView Rating Details
12/1/2017WedbushReiterated RatingBuy$19.00LowView Rating Details
6/1/2017CowenInitiated CoverageOutperformMediumView Rating Details
8/21/2016Rodman & RenshawSet Price TargetBuy$4.00N/AView Rating Details
(Data available from 2/25/2016 forward)

Earnings

Miragen Therapeutics (NASDAQ:MGEN) Earnings History and Estimates Chart

Earnings by Quarter for Miragen Therapeutics (NASDAQ:MGEN)

Miragen Therapeutics (NASDAQ MGEN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017Q3 2017($0.39)($0.27)$0.72 million$1.63 millionViewN/AView Earnings Details
8/11/2017Q2 2017($0.47)($0.34)$0.46 million$0.72 millionViewN/AView Earnings Details
5/10/2017Q1 2017($0.24)($0.60)$1.00 million$0.46 millionViewN/AView Earnings Details
3/24/2017Q4 2016($7.72)$0.76 millionViewN/AView Earnings Details
8/15/2016Q2 2016($4.05)($3.45)$1.00 million$0.87 millionViewN/AView Earnings Details
5/16/2016Q116($0.28)($0.26)$645.00 million$808.00 millionViewN/AView Earnings Details
3/16/2016Q415($0.36)($0.28)$0.60 million$0.66 millionViewN/AView Earnings Details
11/12/2015Q3 2015($5.85)$0.50 millionViewN/AView Earnings Details
8/12/2015Q215($0.39)($0.33)$0.73 millionViewN/AView Earnings Details
5/14/2015Q115($0.36)($0.45)$1.90 million$0.65 millionViewN/AView Earnings Details
3/30/2015($0.39)($1.72)ViewN/AView Earnings Details
11/14/2014Q3 2014($0.05)($0.43)$1.30 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Miragen Therapeutics (NASDAQ:MGEN) Earnings Estimates

2018 EPS Consensus Estimate: ($1.44)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.34)($0.34)($0.34)
Q2 20181($0.35)($0.35)($0.35)
Q3 20181($0.37)($0.37)($0.37)
Q4 20181($0.38)($0.38)($0.38)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Miragen Therapeutics (NASDAQ:MGEN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Miragen Therapeutics (NASDAQ MGEN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 44.40%
Institutional Ownership Percentage: 23.39%
Insider Trades by Quarter for Miragen Therapeutics (NASDAQ:MGEN)
Institutional Ownership by Quarter for Miragen Therapeutics (NASDAQ:MGEN)

Miragen Therapeutics (NASDAQ MGEN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/13/2018Adam Scott LevyInsiderBuy9,090$5.50$49,995.0010,540View SEC Filing  
2/13/2018Bruce BoothDirectorBuy545,454$5.50$2,999,997.00View SEC Filing  
12/20/2017Thomas E. HughesDirectorSell12,000$8.00$96,000.00View SEC Filing  
6/22/2017Adam Scott LevyInsiderBuy200$7.55$1,510.00200View SEC Filing  
3/10/2017Kyle LefkoffDirectorSell5,800$14.34$83,172.00View SEC Filing  
3/8/2017Kyle LefkoffDirectorSell15,000$15.40$231,000.00View SEC Filing  
2/28/2017Kyle LefkoffDirectorSell10,258$13.89$142,483.62View SEC Filing  
2/23/2017Kyle LefkoffDirectorSell5,902$14.14$83,454.28View SEC Filing  
11/20/2015Samuel D. RiccitelliCEOBuy14,000$0.79$11,060.00345,130View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Miragen Therapeutics (NASDAQ MGEN) News Headlines

Source:
DateHeadline
Miragen Therapeutics, Inc. (MGEN) Receives Consensus Recommendation of "Buy" from AnalystsMiragen Therapeutics, Inc. (MGEN) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - February 24 at 9:54 AM
$1.22 Million in Sales Expected for Miragen Therapeutics, Inc. (MGEN) This Quarter$1.22 Million in Sales Expected for Miragen Therapeutics, Inc. (MGEN) This Quarter
www.americanbankingnews.com - February 15 at 6:42 AM
Miragen Therapeutics, Inc. (MGEN) Insider Adam Scott Levy Buys 9,090 SharesMiragen Therapeutics, Inc. (MGEN) Insider Adam Scott Levy Buys 9,090 Shares
www.americanbankingnews.com - February 13 at 6:46 PM
Bruce Booth Purchases 545,454 Shares of Miragen Therapeutics, Inc. (MGEN) StockBruce Booth Purchases 545,454 Shares of Miragen Therapeutics, Inc. (MGEN) Stock
www.americanbankingnews.com - February 13 at 6:10 PM
 Analysts Expect Miragen Therapeutics, Inc. (MGEN) Will Post Earnings of -$0.32 Per Share Analysts Expect Miragen Therapeutics, Inc. (MGEN) Will Post Earnings of -$0.32 Per Share
www.americanbankingnews.com - February 13 at 3:14 AM
miRagen Therapeutics, Inc. Prices Public Offering of Common StockmiRagen Therapeutics, Inc. Prices Public Offering of Common Stock
finance.yahoo.com - February 9 at 5:01 AM
miRagen Therapeutics (MGEN) Announces Proposed 7M Share Common OfferingmiRagen Therapeutics (MGEN) Announces Proposed 7M Share Common Offering
www.streetinsider.com - February 5 at 3:08 PM
miRagen Therapeutics Announces Proposed Public Offering of Common StockmiRagen Therapeutics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - February 5 at 3:08 PM
Miragen Therapeutics (MGEN) Rating Reiterated by CannMiragen Therapeutics (MGEN) Rating Reiterated by Cann
www.americanbankingnews.com - February 2 at 4:46 PM
Miragen Therapeutics, Inc. (MGEN) Receives Average Rating of "Buy" from BrokeragesMiragen Therapeutics, Inc. (MGEN) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - January 30 at 9:39 AM
 Brokerages Anticipate Miragen Therapeutics, Inc. (MGEN) Will Announce Quarterly Sales of $1.22 Million Brokerages Anticipate Miragen Therapeutics, Inc. (MGEN) Will Announce Quarterly Sales of $1.22 Million
www.americanbankingnews.com - January 29 at 8:22 AM
 Brokerages Anticipate Miragen Therapeutics, Inc. (MGEN) Will Announce Earnings of -$0.32 Per Share Brokerages Anticipate Miragen Therapeutics, Inc. (MGEN) Will Announce Earnings of -$0.32 Per Share
www.americanbankingnews.com - January 27 at 5:18 AM
Zacks Investment Research Lowers Miragen Therapeutics (MGEN) to HoldZacks Investment Research Lowers Miragen Therapeutics (MGEN) to Hold
www.americanbankingnews.com - January 25 at 6:50 AM
miRagen Therapeutics to Present New MRG-106 Phase 1 Clinical Trial Data at the T-Cell Lymphoma ForummiRagen Therapeutics to Present New MRG-106 Phase 1 Clinical Trial Data at the T-Cell Lymphoma Forum
finance.yahoo.com - January 24 at 7:07 AM
Chardan Capital Reiterates "Buy" Rating for Miragen Therapeutics (MGEN)Chardan Capital Reiterates "Buy" Rating for Miragen Therapeutics (MGEN)
www.americanbankingnews.com - January 20 at 6:28 AM
Miragen Therapeutics (MGEN) Stock Rating Upgraded by Zacks Investment ResearchMiragen Therapeutics (MGEN) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - January 18 at 8:28 AM
Miragen Therapeutics (MGEN) Downgraded by Zacks Investment ResearchMiragen Therapeutics (MGEN) Downgraded by Zacks Investment Research
www.americanbankingnews.com - January 17 at 6:10 AM
Miragen Therapeutics (MGEN) Coverage Initiated by Analysts at CannMiragen Therapeutics (MGEN) Coverage Initiated by Analysts at Cann
www.americanbankingnews.com - January 14 at 6:40 AM
Oppenheimer Initiates Coverage on Miragen Therapeutics (MGEN)Oppenheimer Initiates Coverage on Miragen Therapeutics (MGEN)
www.americanbankingnews.com - January 13 at 9:36 PM
Miragen Could Surpass $1 Billion In Revenue In 2025, Says Biotech AnalystMiragen Could Surpass $1 Billion In Revenue In 2025, Says Biotech Analyst
feeds.benzinga.com - January 12 at 2:03 PM
Miragen Therapeutics (MGEN) Upgraded to Buy at Zacks Investment ResearchMiragen Therapeutics (MGEN) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - January 9 at 6:08 AM
Miragen Therapeutics (MGEN) Coverage Initiated by Analysts at B. RileyMiragen Therapeutics (MGEN) Coverage Initiated by Analysts at B. Riley
www.americanbankingnews.com - January 6 at 11:50 PM
Zacks Investment Research Downgrades Miragen Therapeutics (MGEN) to HoldZacks Investment Research Downgrades Miragen Therapeutics (MGEN) to Hold
www.americanbankingnews.com - January 6 at 10:04 AM
Where Miragen Therapeutics Inc (NASDAQ:MGEN) Stands In Terms Of Earnings Growth Against Its IndustryWhere Miragen Therapeutics Inc (NASDAQ:MGEN) Stands In Terms Of Earnings Growth Against Its Industry
finance.yahoo.com - January 5 at 4:32 PM
Miragen Therapeutics, Inc. (MGEN) Receives Average Rating of "Buy" from AnalystsMiragen Therapeutics, Inc. (MGEN) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - January 5 at 10:18 AM
miRagen Therapeutics (MGEN) Appoints Arlene Morris to BoardmiRagen Therapeutics (MGEN) Appoints Arlene Morris to Board
www.streetinsider.com - January 5 at 10:14 AM
miRagen Therapeutics Expands Board of Directors with Appointment of Arlene MorrismiRagen Therapeutics Expands Board of Directors with Appointment of Arlene Morris
finance.yahoo.com - January 5 at 10:14 AM
Miragen Therapeutics Inc (NASDAQ:MGEN): Will The Growth Last?Miragen Therapeutics Inc (NASDAQ:MGEN): Will The Growth Last?
finance.yahoo.com - December 29 at 9:20 AM
Can Signal Genetics (MGEN) Run Higher on Strong Earnings Estimate Revisions?Can Signal Genetics (MGEN) Run Higher on Strong Earnings Estimate Revisions?
finance.yahoo.com - December 28 at 4:35 PM
Miragen Therapeutics, Inc. (MGEN) Director Thomas E. Hughes Sells 12,000 SharesMiragen Therapeutics, Inc. (MGEN) Director Thomas E. Hughes Sells 12,000 Shares
www.americanbankingnews.com - December 22 at 8:39 PM
Miragen Therapeutics IncMiragen Therapeutics Inc
www.bloomberg.com - December 21 at 4:50 PM
ETFs with exposure to Miragen Therapeutics, Inc. : December 21, 2017ETFs with exposure to Miragen Therapeutics, Inc. : December 21, 2017
finance.yahoo.com - December 21 at 4:50 PM
miRagen Therapeutics Presents New Interim Clinical Data Expanding on Previous Data Suggesting Positive Impact From Systemically Administered MRG-106 on Mycosis Fungoides Form of Cutaneous T-Cell Lymphoma at 2017 American Society of Hematology Annual MeetingmiRagen Therapeutics Presents New Interim Clinical Data Expanding on Previous Data Suggesting Positive Impact From Systemically Administered MRG-106 on Mycosis Fungoides Form of Cutaneous T-Cell Lymphoma at 2017 American Society of Hematology Annual Meeting
finance.yahoo.com - December 11 at 4:58 PM
Head to Head Survey: Cannabis Science (CBIS) and Miragen Therapeutics (MGEN)Head to Head Survey: Cannabis Science (CBIS) and Miragen Therapeutics (MGEN)
www.americanbankingnews.com - December 8 at 7:42 PM
Financial Review: Miragen Therapeutics (MGEN) vs. BG Medicine (BGMD)Financial Review: Miragen Therapeutics (MGEN) vs. BG Medicine (BGMD)
www.americanbankingnews.com - December 8 at 5:14 PM
BG Medicine (BGMD) vs. Miragen Therapeutics (MGEN) Head-To-Head AnalysisBG Medicine (BGMD) vs. Miragen Therapeutics (MGEN) Head-To-Head Analysis
www.americanbankingnews.com - December 6 at 3:12 AM
Top Insiders Are Buying These 3 Strong Buy Healthcare StocksTop Insiders Are Buying These 3 'Strong Buy' Healthcare Stocks
www.nasdaq.com - December 4 at 4:47 PM
Financial Analysis: Signal Genetics (MGEN) vs. BG Medicine (BGMD)Financial Analysis: Signal Genetics (MGEN) vs. BG Medicine (BGMD)
www.americanbankingnews.com - December 3 at 4:38 PM
Reviewing Cannabis Science (CBIS) and Signal Genetics (MGEN)Reviewing Cannabis Science (CBIS) and Signal Genetics (MGEN)
www.americanbankingnews.com - December 2 at 1:30 AM
Signal Genetics (MGEN) Earns Buy Rating from WedbushSignal Genetics (MGEN) Earns Buy Rating from Wedbush
www.americanbankingnews.com - December 1 at 4:12 PM
Head to Head Comparison: Signal Genetics (MGEN) versus BG Medicine (BGMD)Head to Head Comparison: Signal Genetics (MGEN) versus BG Medicine (BGMD)
www.americanbankingnews.com - December 1 at 3:54 PM
Head-To-Head Contrast: Cannabis Science (CBIS) and Signal Genetics (MGEN)Head-To-Head Contrast: Cannabis Science (CBIS) and Signal Genetics (MGEN)
www.americanbankingnews.com - November 30 at 1:28 AM
Head to Head Analysis: Cannabis Science (CBIS) versus Signal Genetics (MGEN)Head to Head Analysis: Cannabis Science (CBIS) versus Signal Genetics (MGEN)
www.americanbankingnews.com - November 27 at 10:58 AM
Cannabis Science (CBIS) & Signal Genetics (MGEN) Head-To-Head ReviewCannabis Science (CBIS) & Signal Genetics (MGEN) Head-To-Head Review
www.americanbankingnews.com - November 22 at 3:42 PM
Contrasting Cannabis Science (CBIS) & Signal Genetics (MGEN)Contrasting Cannabis Science (CBIS) & Signal Genetics (MGEN)
www.americanbankingnews.com - November 21 at 5:52 PM
BG Medicine (BGMD) and Signal Genetics (MGEN) Critical SurveyBG Medicine (BGMD) and Signal Genetics (MGEN) Critical Survey
www.americanbankingnews.com - November 21 at 1:52 PM
BG Medicine (BGMD) and Signal Genetics (MGEN) Head to Head ReviewBG Medicine (BGMD) and Signal Genetics (MGEN) Head to Head Review
www.americanbankingnews.com - November 20 at 1:30 AM
Signal Genetics, Inc. (MGEN) Stock Rating Upgraded by Zacks Investment ResearchSignal Genetics, Inc. (MGEN) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - November 18 at 6:56 PM
Cannabis Science (CBIS) versus Signal Genetics (MGEN) Critical ReviewCannabis Science (CBIS) versus Signal Genetics (MGEN) Critical Review
www.americanbankingnews.com - November 17 at 3:08 AM
Cannabis Science (CBIS) vs. Signal Genetics (MGEN) Head to Head SurveyCannabis Science (CBIS) vs. Signal Genetics (MGEN) Head to Head Survey
www.americanbankingnews.com - November 16 at 11:14 PM

SEC Filings

Miragen Therapeutics (NASDAQ:MGEN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Miragen Therapeutics (NASDAQ:MGEN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Miragen Therapeutics (NASDAQ MGEN) Stock Chart for Sunday, February, 25, 2018

Loading chart…

This page was last updated on 2/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.